Andrew D. Abell, Professor of The University of Adelaide, Adelaide, Australia. Andrew graduated from the University of Adelaide with BSc(Hon) and PhD and then undertook a postdoctoral fellowship at the University of Cambridge. He held a professorship at the University of Canterbury before returning to the University of Adelaide in 2007, where he is currently Professor of Chemistry and node director of the ARC Centre of Excellence for Nanoscale Biophotonics. His research interests are concerned with understanding the fundamental link between the chemical structure and shape of key biological molecules and their biological function. While his work is very much driven by fundamental science, he has always had a keen interest in pursuing associated commercial opportunities. The seed for this was sown with a sabbatical leave working as a visiting scientist, consultant and senior Fulbright Fellow with SmithKline Beecham (now GSK) in Philadelphia. In Adelaide he co-founded an Adelaide-based company (Calpain Therapeutics) to develop macrocyclic protease inhibitors as a potential treatment for cataract and other conditions. Past member of ARC College of Experts and Head of School of Chemistry and Physics at the University of Adelaide and also recent recipient of the Royal Australian Chemical Institute Adrien Albert Prize and the Alexander R. Matzuk Prize and Lecture in Drug Discovery (Baylor College of Medicine, Houston).
